| Dr Douglas Reed Lawler Ii, MD | |
|
351 Court St, Abingdon, VA 24210-2921 | |
| (276) 676-7000 | |
| (276) 676-9366 |
| Full Name | Dr Douglas Reed Lawler Ii |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Location | 351 Court St, Abingdon, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467563239 | NPI | - | NPPES |
| 7100150100 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 0101042381 (Virginia) | Primary |
| 207Q00000X | Family Medicine | 0101042381 (Virginia) | Secondary |
| Entity Name | Johnston Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104812684 PECOS PAC ID: 6103725668 Enrollment ID: O20040103000016 |
News Archive
Proteomic analysis using mass spectrometry could be used in a diagnostic test for sleeping sickness that can more accurately spot the disease than current approaches.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.
A single session of a gene therapy developed by the Universitat Autònoma de Barcelona (UAB) cures Sanfilippo Syndrome A in animal models. This syndrome is a neurodegenerative disease that affects between 1 and 9 out of every 100,000 children, and causes the death of the child on reaching adolescence.
› Verified 1 days ago
| Entity Name | Appalachian Emergency Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487963781 PECOS PAC ID: 6901099639 Enrollment ID: O20110120000558 |
News Archive
Proteomic analysis using mass spectrometry could be used in a diagnostic test for sleeping sickness that can more accurately spot the disease than current approaches.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.
A single session of a gene therapy developed by the Universitat Autònoma de Barcelona (UAB) cures Sanfilippo Syndrome A in animal models. This syndrome is a neurodegenerative disease that affects between 1 and 9 out of every 100,000 children, and causes the death of the child on reaching adolescence.
› Verified 1 days ago
| Entity Name | Western Virginia Regional Emergency Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386183028 PECOS PAC ID: 4183991227 Enrollment ID: O20170522001368 |
News Archive
Proteomic analysis using mass spectrometry could be used in a diagnostic test for sleeping sickness that can more accurately spot the disease than current approaches.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.
A single session of a gene therapy developed by the Universitat Autònoma de Barcelona (UAB) cures Sanfilippo Syndrome A in animal models. This syndrome is a neurodegenerative disease that affects between 1 and 9 out of every 100,000 children, and causes the death of the child on reaching adolescence.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Douglas Reed Lawler Ii, MD 18377 Lake Rd, Abingdon, VA 24211-5337 Ph: (276) 676-3150 | Dr Douglas Reed Lawler Ii, MD 351 Court St, Abingdon, VA 24210-2921 Ph: (276) 676-7000 |
News Archive
Proteomic analysis using mass spectrometry could be used in a diagnostic test for sleeping sickness that can more accurately spot the disease than current approaches.
Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.
Syndax Pharmaceuticals, Inc. announced today that data from ENGAGE 501, a multicenter, phase 2 study, demonstrated entinostat, a novel, oral small molecule inhibitor of class I histone deacetylases, showed activity as a single agent in patients with relapsed or refractory Hodgkin's lymphoma.
A single session of a gene therapy developed by the Universitat Autònoma de Barcelona (UAB) cures Sanfilippo Syndrome A in animal models. This syndrome is a neurodegenerative disease that affects between 1 and 9 out of every 100,000 children, and causes the death of the child on reaching adolescence.
› Verified 1 days ago
Dr. Sarah S Carrier, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 351 Court St, Abingdon, VA 24210 Phone: 276-676-7000 Fax: 276-676-9366 | |
Dr. David W Hale Jr., DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 351 Court St, Abingdon, VA 24210 Phone: 276-676-7000 | |
Dr. Brian Christopher Dawson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr, Abingdon, VA 24211 Phone: 276-258-1100 Fax: 276-258-1125 | |
Dr. Steven M Bandy, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 16000 Johnston Memorial Dr, Abingdon, VA 24211 Phone: 276-258-1100 Fax: 276-258-1125 | |
Dr. Brett L Tooley, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr, Abingdon, VA 24211 Phone: 352-262-2844 | |
Dr. Kelly Anne Carter, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 16000 Johnston Memorial Dr, Abingdon, VA 24211 Phone: 276-258-1100 Fax: 276-258-1125 | |
Dr. Simon P Pennings, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 613 Campus Dr, Suite 200, Abingdon, VA 24210 Phone: 276-628-1186 Fax: 276-628-8507 |